mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model.

Saved in:

Bibliographic Details
Title:	mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model.
Authors:	Sittplangkoon C; Graduate Program in Biotechnology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.; Center of Excellence in Immunology and Immune-Mediated Diseases, Chulalongkorn University, Bangkok, Thailand., Alameh MG; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States., Weissman D; Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States., Lin PJC; Acuitas Therapeutics, Vancouver, BC, Canada., Tam YK; Acuitas Therapeutics, Vancouver, BC, Canada., Prompetchara E; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center-Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Palaga T; Center of Excellence in Immunology and Immune-Mediated Diseases, Chulalongkorn University, Bangkok, Thailand.; Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Source:	Frontiers in immunology [Front Immunol] 2022 Oct 14; Vol. 13, pp. 983000. Date of Electronic Publication: 2022 Oct 14 (Print Publication: 2022).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2022.983000